show 
Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs
Johansson, P.O.; Chen, Y.; Belfrage, A.K.; Blackman, M.J.; Kvarnstroem, I.; Jansson, K.; Vrang, L.; Hamelink, E.; Hallberg, A.; Rosenquist, A.; Samuelsson, B.; J. Med. Chem. 47, 3353-3366 (2004)
Data extracted from this reference:
Inhibitors
Inhibitors
Commentary
Organism
Structure
(3S,4S)-5-(4-bromobenzyloxy)-3-hydroxy-4-(2-thiophen-2-ylacetylamino)pentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
(3S,4S)-5-(4-bromobenzyloxy)-4-(3,3-diphenylpropionylamino)-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
(3S,4S)-5-(4-bromobenzyloxy)-4-diphenylacetylamino-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
(S)-2,3-dihydro-1H-indole-2-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)amide
-
Plasmodium falciparum
benzo[1,3]dioxole-5-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-amide
-
Plasmodium falciparum
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-[2-(3-methoxyphenyl)ethylcarbamoyl]propyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-3,4-dichlorobenzamide
-
Plasmodium falciparum
N-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((R)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-(3-methoxyphenyl)ethylcarbamoyl)propylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-benzyloxymethyl-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxy-1-phenethylpropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-phenylaminoethyl-carbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-methoxypropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-phenylpropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(4-cyanobenzylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(cyclohexylmethylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-butylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Plasmodium falciparum
-
-
-
Ki Value [mM]
Ki Value [mM]
Ki Value maximum [mM]
Inhibitor
Commentary
Organism
Structure
0.0022
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.01
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
0.011
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-benzyloxymethyl-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.015
-
pyridine-2-carboxylic acid ((R)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.025
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.029
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-(3-methoxyphenyl)ethylcarbamoyl)propylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.03
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-phenylpropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.041
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(cyclohexylmethylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.046
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxy-1-phenethylpropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.068
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-butylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.074
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-phenylaminoethyl-carbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.091
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-3,4-dichlorobenzamide
-
Plasmodium falciparum
0.131
-
benzo[1,3]dioxole-5-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-amide
-
Plasmodium falciparum
0.139
-
(3S,4S)-5-(4-bromobenzyloxy)-4-diphenylacetylamino-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
0.144
-
(S)-2,3-dihydro-1H-indole-2-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)amide
-
Plasmodium falciparum
0.23
-
N-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
0.248
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-methoxypropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.256
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(4-cyanobenzylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.284
-
(3S,4S)-5-(4-bromobenzyloxy)-4-(3,3-diphenylpropionylamino)-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
0.348
-
(3S,4S)-5-(4-bromobenzyloxy)-3-hydroxy-4-(2-thiophen-2-ylacetylamino)pentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
0.39
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-[2-(3-methoxyphenyl)ethylcarbamoyl]propyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
Inhibitors (protein specific)
Inhibitors
Commentary
Organism
Structure
(3S,4S)-5-(4-bromobenzyloxy)-3-hydroxy-4-(2-thiophen-2-ylacetylamino)pentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
(3S,4S)-5-(4-bromobenzyloxy)-4-(3,3-diphenylpropionylamino)-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
(3S,4S)-5-(4-bromobenzyloxy)-4-diphenylacetylamino-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
(S)-2,3-dihydro-1H-indole-2-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)amide
-
Plasmodium falciparum
benzo[1,3]dioxole-5-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-amide
-
Plasmodium falciparum
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-[2-(3-methoxyphenyl)ethylcarbamoyl]propyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-3,4-dichlorobenzamide
-
Plasmodium falciparum
N-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((R)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-(3-methoxyphenyl)ethylcarbamoyl)propylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-benzyloxymethyl-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxy-1-phenethylpropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-phenylaminoethyl-carbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-methoxypropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-phenylpropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(4-cyanobenzylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(cyclohexylmethylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-butylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
Ki Value [mM] (protein specific)
Ki Value [mM]
Ki Value maximum [mM]
Inhibitor
Commentary
Organism
Structure
0.0022
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.01
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
0.011
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-benzyloxymethyl-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.015
-
pyridine-2-carboxylic acid ((R)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.025
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.029
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-(3-methoxyphenyl)ethylcarbamoyl)propylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.03
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-phenylpropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.041
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(cyclohexylmethylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.046
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxy-1-phenethylpropylcarbamoyl)-2-methylpropyl)amide
-
Plasmodium falciparum
0.068
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-butylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.074
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-phenylaminoethyl-carbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.091
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-3,4-dichlorobenzamide
-
Plasmodium falciparum
0.131
-
benzo[1,3]dioxole-5-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-amide
-
Plasmodium falciparum
0.139
-
(3S,4S)-5-(4-bromobenzyloxy)-4-diphenylacetylamino-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
0.144
-
(S)-2,3-dihydro-1H-indole-2-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)amide
-
Plasmodium falciparum
0.23
-
N-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
0.248
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-methoxypropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.256
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(4-cyanobenzylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
Plasmodium falciparum
0.284
-
(3S,4S)-5-(4-bromobenzyloxy)-4-(3,3-diphenylpropionylamino)-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
0.348
-
(3S,4S)-5-(4-bromobenzyloxy)-3-hydroxy-4-(2-thiophen-2-ylacetylamino)pentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
Plasmodium falciparum
0.39
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-[2-(3-methoxyphenyl)ethylcarbamoyl]propyl)-2,4,6-trifluorobenzamide
-
Plasmodium falciparum
Other publictions for EC 3.4.23.39
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [°C]
Temperature Range [°C]
Temperature Stability [°C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [°C] (protein specific)
Temperature Range [°C] (protein specific)
Temperature Stability [°C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
717364
Saify
New benzimidazole derivatives ...
Plasmodium falciparum
Bioorg. Med. Chem. Lett.
22
1282-1286
2012
-
-
-
1
-
-
3
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
1
-
-
3
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
717158
Xiao
The native conformation of pla ...
Plasmodium falciparum
Arch. Biochem. Biophys.
513
102-109
2011
-
-
1
-
-
-
-
-
-
-
-
-
-
2
-
1
-
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
717478
Dali
Insight into selectivity of pe ...
Plasmodium falciparum
Chem. Biol. Drug Des.
79
411-430
2011
-
-
-
1
-
-
3
-
1
-
-
-
-
3
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
1
-
-
3
3
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
708127
Luksch
Pyrrolidine derivatives as pla ...
Plasmodium falciparum
ChemMedChem
5
443-454
2010
-
-
-
-
-
-
10
1
1
-
-
-
-
3
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
10
-
-
-
-
-
-
-
-
-
-
10
10
1
1
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
708888
Marcoux
Investigating alternative acid ...
Plasmodium falciparum
J. Am. Soc. Mass Spectrom.
21
76-79
2010
-
1
1
-
-
-
-
-
-
-
2
1
-
2
-
1
1
-
-
-
-
-
4
-
2
-
-
-
2
-
-
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
2
1
-
-
1
1
-
-
-
-
4
-
2
-
-
-
2
-
-
-
-
-
-
-
-
-
709167
Mohapatra
Antimalarial evaluation of cop ...
Plasmodium falciparum
J. Biol. Inorg. Chem.
15
373-385
2010
-
-
1
-
-
-
3
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
2
-
1
-
-
-
1
-
-
-
2
-
2
-
-
1
-
-
-
-
2
3
2
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
709477
Gupta
Mechanism-based inhibitors of ...
Plasmodium falciparum
J. Med. Chem.
53
4234-4247
2010
-
-
1
-
-
-
4
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
1
-
1
-
-
-
1
-
-
-
2
-
4
-
-
1
-
-
-
-
4
4
2
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
710468
Parr-Vasquez
Functional chimera of porcine ...
Plasmodium falciparum
Protein Eng. Des. Sel.
23
19-26
2010
-
-
1
-
1
-
1
3
-
-
-
-
-
4
-
1
1
-
-
-
-
-
1
-
-
-
-
3
1
1
-
-
-
-
-
-
-
1
-
-
1
-
-
1
-
3
-
-
-
-
-
-
1
1
-
-
-
-
1
-
-
-
-
3
1
1
-
-
-
-
-
-
3
3
695327
Robbins
Crystallographic evidence for ...
Plasmodium falciparum
Acta Crystallogr. Sect. D
65
294-296
2009
-
-
-
1
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
696871
Ramirez
Generation of an affinity matr ...
Plasmodium falciparum
Biotechnol. Appl. Biochem.
52
149-157
2009
-
-
-
-
-
-
3
1
-
-
-
-
-
4
-
-
-
-
-
-
-
-
2
-
-
-
-
1
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
3
2
1
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
707169
Moura
Role of Plasmodium falciparum ...
Plasmodium falciparum
Antimicrob. Agents Chemother.
53
4968-4978
2009
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
708120
Degliesposti
Design and discovery of plasme ...
Plasmodium falciparum
ChemMedChem
4
1164-1173
2009
-
-
1
-
-
-
31
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
1
-
1
-
-
-
1
-
-
-
-
-
27
-
-
1
-
-
-
-
27
31
-
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
708121
Friedman
Discovery of plasmepsin inhibi ...
Plasmodium falciparum
ChemMedChem
4
1317-1326
2009
-
-
-
-
-
-
14
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
14
-
-
-
-
-
-
-
14
14
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
710185
Faeh
New organofluorine building bl ...
Plasmodium falciparum
Org. Biomol. Chem.
7
3947-3957
2009
-
-
-
-
-
-
14
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
14
-
-
-
-
-
-
-
14
14
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
691814
Luksch
Computer-aided design and synt ...
Plasmodium falciparum
ChemMedChem
3
1323-1336
2008
-
-
-
-
-
-
5
-
1
-
-
-
-
3
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
5
-
-
-
-
-
-
-
-
-
-
5
5
-
1
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
696706
Hidaka
Antimalarial activity enhancem ...
Plasmodium falciparum
Bioorg. Med. Chem.
16
10049-10060
2008
-
-
-
1
-
-
5
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
5
-
-
-
-
-
-
1
-
-
-
5
5
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
701128
Valiente
Predicting functional residues ...
Plasmodium falciparum
Proteins
73
440-457
2008
-
-
-
1
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
701129
Friedman
Pepsinogen-like activation int ...
Plasmodium falciparum
Proteins
73
814-827
2008
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
679136
Bjelic
Computational inhibitor design ...
Plasmodium falciparum
Cell. Mol. Life Sci.
64
2285-2305
2007
-
-
-
-
-
-
25
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
679867
Friedman
The protonation state of the c ...
Plasmodium sp.
FEBS Lett.
581
4120-4124
2007
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
682004
Bonilla
Critical roles for the digesti ...
Plasmodium falciparum
Mol. Microbiol.
65
64-75
2007
-
-
-
-
-
-
-
-
3
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
667927
Ersmark
Macrocyclic inhibitors of the ...
Plasmodium falciparum
Bioorg. Med. Chem.
14
2197-2208
2006
-
-
-
-
-
-
5
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5
-
-
-
-
-
-
-
-
-
-
5
5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
667988
Corminboeuf
Inhibitors of plasmepsin II-po ...
Plasmodium falciparum
Bioorg. Med. Chem. Lett.
16
6194-6199
2006
-
-
-
-
-
-
51
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
53
-
-
-
-
-
-
-
53
51
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
669157
Kim
Prodomain processing of recomb ...
Plasmodium falciparum
J. Biochem.
139
189-195
2006
-
-
1
-
4
-
2
-
1
-
-
-
-
2
-
1
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
4
-
-
2
-
-
1
-
-
-
-
-
1
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
670126
Ersmark
Plasmepsins as potential targe ...
Plasmodium falciparum
Med. Res. Rev.
26
626-666
2006
-
-
-
1
-
-
50
-
-
-
-
-
-
5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
50
-
-
-
-
-
-
1
-
-
-
50
50
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
677552
Hof
Starving the malaria parasite: ...
Plasmodium falciparum
Angew. Chem.
45
2138-2141
2006
-
-
-
-
-
-
5
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5
-
-
-
-
-
-
-
5
5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
679228
Boss
Achiral, cheap, and potent inh ...
Plasmodium falciparum
ChemMedChem
1
1341-1345
2006
-
-
-
-
-
-
16
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
16
-
-
-
-
-
-
-
16
16
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
680725
Liu
Hemoglobin-degrading plasmepsi ...
Plasmodium sp.
J. Biol. Chem.
281
38682-38688
2006
-
-
-
-
4
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
681296
DellAgli
High antiplasmodial activity o ...
Plasmodium falciparum
J. Med. Chem.
49
7440-7449
2006
-
-
-
-
-
-
10
-
-
-
-
-
-
3
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
10
-
-
-
-
-
-
-
-
-
-
10
10
-
-
-
-
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
669349
Prade
X-ray structure of plasmepsin ...
Plasmodium falciparum
J. Biol. Chem.
280
23837-23843
2005
-
-
1
1
-
-
1
-
-
-
-
1
-
2
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
1
-
-
-
1
-
-
-
-
-
1
-
-
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
669426
Istvan
Distal substrate interactions ...
Plasmodium falciparum
J. Biol. Chem.
280
6890-6896
2005
-
-
-
-
-
-
-
12
-
-
-
-
-
2
-
-
1
-
-
-
-
-
3
-
-
-
-
14
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12
-
-
-
-
-
-
-
1
-
-
-
-
3
-
-
-
-
14
-
-
-
-
-
-
-
-
-
-
669779
Johansson
Design and synthesis of potent ...
Plasmodium falciparum
J. Med. Chem.
48
4400-4409
2005
-
-
-
1
-
-
18
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
16
-
-
-
-
-
-
1
-
-
-
18
16
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648181
Ersmark
Potent inhibitors of the Plasm ...
Plasmodium falciparum
J. Med. Chem.
47
110-122
2004
-
-
-
-
-
-
17
-
-
-
-
-
-
3
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
16
-
-
-
-
-
-
-
-
-
-
17
16
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
667942
Romeo
Plasmepsin II inhibition and a ...
Plasmodium falciparum
Bioorg. Med. Chem. Lett.
14
2931-2934
2004
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
668255
Boss
-
Inhibitors of plasmepsin II - ...
Plasmodium falciparum
Chimia
58
634-639
2004
-
1
-
-
-
-
57
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
60
-
1
-
-
-
-
-
60
57
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
669571
Klemba
Trafficking of plasmepsin II t ...
Plasmodium falciparum
J. Cell Biol.
164
47-56
2004
-
-
-
-
-
-
-
-
2
-
-
1
-
2
-
1
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
1
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
669770
Johansson
Design and synthesis of potent ...
Plasmodium falciparum
J. Med. Chem.
47
3353-3366
2004
-
-
-
-
-
-
21
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
21
-
-
-
-
-
-
-
-
-
-
21
21
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
669984
Kiso
Search for substrate-based inh ...
Plasmodium falciparum
J. Pept. Sci.
10
641-647
2004
-
1
-
-
-
-
1
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
669987
Salas
A heterogeneous enzymatic assa ...
Plasmodium falciparum
J. Pharm. Biomed. Anal.
34
833-840
2004
-
1
-
-
-
-
1
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648183
Dahlgren
New inhibitors of the malaria ...
Plasmodium falciparum
Bioorg. Med. Chem.
11
3423-3437
2003
-
-
-
-
-
-
12
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
12
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648186
Noteberg
Design and synthesis of plasme ...
Plasmodium falciparum
J. Med. Chem.
46
734-746
2003
-
-
-
-
-
-
12
-
-
-
-
-
-
3
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
11
-
-
-
-
-
-
-
-
-
-
12
11
-
-
-
-
-
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648205
Asojo
Novel uncomplexed and complexe ...
Plasmodium falciparum
J. Mol. Biol.
327
173-181
2003
-
-
-
1
-
-
1
-
-
-
-
-
-
5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648187
Siripurkpong
Active Site Contribution to Sp ...
Plasmodium falciparum
J. Biol. Chem.
277
41009-41013
2002
-
-
1
-
1
-
2
1
-
-
-
1
-
2
-
-
1
-
-
-
-
-
2
-
-
-
-
1
-
-
-
-
1
-
1
-
-
1
-
-
1
-
1
2
1
1
-
-
-
1
-
-
-
1
-
-
-
-
2
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
648204
Asojo
Structures of Ser205 mutant pl ...
Plasmodium falciparum
Acta Crystallogr. Sect. D
58
2001-2008
2002
-
-
-
1
1
-
3
-
2
-
-
1
-
2
-
-
-
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
3
-
-
2
-
-
1
-
-
-
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648182
Berry
Plasmepsins as antimalarial ta ...
Plasmodium falciparum
Curr. Opin. Drug Discov. Devel.
3
624-629
2000
-
-
-
1
-
-
6
-
-
-
-
1
-
1
-
1
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
1
-
-
-
6
3
-
-
-
-
1
-
-
1
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648188
Tyas
Naturally-occurring and recomb ...
Plasmodium falciparum
FEBS Lett.
454
210-214
1999
-
-
-
-
-
-
3
6
-
-
-
-
-
3
-
-
-
-
-
-
-
-
5
-
-
-
-
8
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
3
3
6
-
-
-
-
-
-
-
-
-
-
-
-
5
-
-
-
-
8
-
-
-
-
-
-
-
-
-
-
648203
Bernstein
Crystal structure of the novel ...
Plasmodium falciparum
Nat. Struct. Biol.
6
32-37
1999
-
-
-
1
-
-
-
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648206
Westling
Active site specificity of pla ...
Plasmodium falciparum
Protein Sci.
8
2001-2009
1999
-
-
-
-
4
-
-
64
-
-
-
-
-
2
-
-
-
-
-
-
-
-
27
-
-
-
-
61
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
64
-
-
-
-
-
-
-
-
-
-
-
-
27
-
-
-
-
61
-
-
-
-
-
-
-
-
-
-
648207
Haque
Potent, low-molecular-weight n ...
Plasmodium falciparum
J. Med. Chem.
42
1428-1440
1999
-
-
-
-
-
-
21
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12
-
-
-
-
-
-
-
-
-
-
21
12
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648208
Le Bonniec
Plasmepsin II, an acidic hemog ...
Plasmodium falciparum
J. Biol. Chem.
274
14218-14223
1999
-
-
-
-
-
-
-
-
5
-
-
2
-
4
-
-
-
-
-
2
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5
-
-
2
-
-
-
-
-
2
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648185
Moon
Studies on plasmepsins I and I ...
Plasmodium falciparum
Adv. Exp. Med. Biol.
436
397-406
1998
-
-
-
1
-
-
2
-
-
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
1
-
-
-
2
2
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648189
Tyas
Plasmepsins I and II from the ...
Plasmodium falciparum
Adv. Exp. Med. Biol.
436
407-411
1998
-
-
1
-
-
-
3
4
-
-
-
1
-
1
-
-
-
-
-
-
-
-
6
-
-
-
-
5
1
1
-
-
3
-
-
-
-
1
-
-
-
-
-
3
3
4
-
-
-
1
-
-
-
-
-
-
-
-
6
-
-
-
-
5
1
1
-
-
-
-
-
-
-
-
648184
Francis
Biosynthesis and maturation of ...
Plasmodium falciparum
J. Biol. Chem.
272
14961-14968
1997
-
-
-
-
-
-
-
-
2
-
-
-
-
2
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648190
Moon
Expression and characterizatio ...
Plasmodium falciparum
Eur. J. Biochem.
244
552-560
1997
-
-
1
-
-
-
4
2
-
-
-
-
-
3
-
1
1
-
-
1
-
-
2
-
-
-
-
2
-
1
-
-
4
-
-
-
-
1
-
-
-
-
-
4
4
2
-
-
-
-
-
-
1
1
-
1
-
-
2
-
-
-
-
2
-
1
-
-
-
-
-
-
-
-
648180
Gluzman
Order and specificity of the P ...
Plasmodium falciparum
J. Clin. Invest.
93
1602-1608
1994
-
-
-
-
-
-
2
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
648193
Hill
High level expression and char ...
Plasmodium falciparum
FEBS Lett.
352
155-158
1994
-
-
1
-
-
-
5
2
-
-
-
-
-
3
-
-
1
-
-
-
-
-
4
-
-
-
-
3
-
-
-
-
-
-
5
-
-
1
-
-
-
-
5
5
-
2
-
-
-
-
-
-
-
1
-
-
-
-
4
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
648194
Dame
Sequence, expression and model ...
Plasmodium falciparum, Plasmodium falciparum HB3
Mol. Biochem. Parasitol.
64
177-190
1994
-
-
1
-
-
-
2
-
1
-
1
2
-
6
-
-
-
-
-
-
-
-
2
1
-
-
-
-
1
1
-
-
1
-
-
-
-
1
-
-
-
-
-
2
1
-
1
-
1
2
-
-
-
-
-
-
-
-
2
1
-
-
-
-
1
1
-
-
-
-
-
-
-
-